Introduction of stearoyl moieties into a biocompatible cationic polyaspartamide derivative, PAsp(DET), with endosomal escaping function for enhanced siRNA-mediated gene knockdown.
Applications of siRNA for cancer therapy have been spotlighted in recent years, but the rational design of efficient siRNA delivery carriers is still controversial, especially because of possible toxicity of the carrier components. Previously, a cationic polyaspartamide derivative, poly{N-[N-(2-aminoethyl)-2-aminoethyl]aspartamide} (PAsp(DET)), was reported to exert high transfection efficacy for plasmid DNA with negligible cytotoxicity. However, its direct application for siRNA delivery was fairly limited due to the unstable polymer/siRNA complex formation. In this study, to overcome such instability, stearic acid as a hydrophobic moiety was conjugated to the side chain of PAsp(DET) with various substitution degrees. The stearoyl introduction contributed not only to siRNA complex formation with higher association numbers but also to complex stabilization. The obtained stearoyl PAsp(DET)/siRNA complex significantly accomplished more efficient endogenous gene (BCL-2 and VEGF) knockdown in vitro against the human pancreatic adenocarcinoma (Panc-1) cells than did the unmodified PAsp(DET) complex and commercially available reagents, probably due to the facilitated cellular internalization. This finding suggests that the hydrophobic PAsp(DET)-mediated siRNA delivery is a promising platform for in vivo siRNA delivery.
Kim
Hyun Jin
HJ
Department of Materials Engineering, Graduate School of Engineering, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8656, Japan.
Ishii
Atsushi
A
Miyata
Kanjiro
K
Lee
Yan
Y
Wu
Shourong
S
Oba
Makoto
M
Nishiyama
Nobuhiro
N
Kataoka
Kazunori
K
D000818:Animals; D001672:Biocompatible Materials / Q000737:chemistry; D002412:Cations / Q000737:chemistry; D045744:Cell Line, Tumor; D003520:Cyclophosphamide / Q000031:analogs & derivatives* / Q000737:chemistry; D011992:Endosomes / Q000737:chemistry*; D055785:Gene Knockdown Techniques; D019254:Genes, bcl-2; D006801:Humans; D008546:Melanoma, Experimental / Q000628:therapy; D051379:Mice; D010190:Pancreatic Neoplasms / Q000628:therapy; D010957:Plasmids / Q000378:metabolism; D011108:Polymers / Q000737:chemistry; D034741:RNA, Small Interfering / Q000378:metabolism* / Q000627:therapeutic use; D014162:Transfection / Q000379:methods
D001672:Biocompatible Materials; D002412:Cations; D011108:Polymers; D034741:RNA, Small Interfering; C028136:4-S-(propionic acid)sulfidocyclophosphamide; D003520:Cyclophosphamide